Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Phase 3

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: Atezolizumab
Drug: Irinotecan (CPT-11)
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil (5-FU)

First Posted Date: 2024-12-13

Last Posted Date: 2024-12-16

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 238

Registration Number: NCT06733038

Locations: 🇮🇹
Istituto Oncologico Veneto Irccs, Padova, PD, Italy
🇮🇹
Nuovo Ospedale di Prato S. Stefano, Prato, PO, Italy
🇮🇹
U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa, Italy

Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Phase 2

Not yet recruiting

Conditions: Advanced Lung Non-Small Cell Carcinoma
Metastatic Lung Non-Small Cell Carcinoma
Stage III Lung Cancer AJCC V8
Stage IV Lung Cancer AJCC V8

Interventions: Biological: Atezolizumab
Procedure: Biospecimen Collection
Biological: Cemiplimab
Procedure: Computed Tomography
Drug: Diclofenac Potassium
Other: Electronic Health Record Review
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab
Biological: Pembrolizumab
Procedure: Positron Emission Tomography

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: Emory University

Target Recruit Count: 20

Registration Number: NCT06731270

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: M9466
Drug: Etoposide
Drug: Carboplatin
Drug: Atezolizumab
Drug: M9446

First Posted Date: 2024-12-06

Last Posted Date: 2024-12-06

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 54

Registration Number: NCT06719973

Locations: 🇺🇸
Please Contact U.S. Medical Information, Billerica, Massachusetts, United States
🇩🇪
Please Contact the Communication Center, Darmstadt, Germany

Safety and Effectiveness of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Phase 3

Not yet recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Drug: Atezolizumab
Drug: BNT327
Drug: Etoposide
Drug: Carboplatin

First Posted Date: 2024-12-02

Last Posted Date: 2024-12-02

Lead Sponsor: BioNTech SE

Target Recruit Count: 439

Registration Number: NCT06712355

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-18

Lead Sponsor: Peking University Shenzhen Hospital

Target Recruit Count: 200

Registration Number: NCT06692491

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Phase 3

Not yet recruiting

Conditions: Hepatocellular Carcinoma (HCC)

Interventions: Biological: Atezolizumab
Drug: TPST-1120
Biological: Bevacizumab

First Posted Date: 2024-11-08

Last Posted Date: 2024-11-08

Lead Sponsor: Tempest Therapeutics

Target Recruit Count: 740

Registration Number: NCT06680258

Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Phase 2

Not yet recruiting

Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Interventions: Drug: Atezolizumab
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2024-10-29

Last Posted Date: 2024-10-29

Lead Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica

Target Recruit Count: 142

Registration Number: NCT06663098

Locations: 🇮🇹
Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy
🇮🇹
IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
🇮🇹
IRCCS Azienda Ospedaliero_Universitaria di Bologna, Bologna, Italy

and more 22 locations

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Phase 3

Not yet recruiting

Conditions: Extensive-Stage Small Cell Lung Cancer

Interventions: Biological: BMS-986489 (BMS-986012+Nivolumab)
Biological: Atezolizumab
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2024-10-17

Last Posted Date: 2024-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 530

Registration Number: NCT06646276

Locations: 🇨🇳
Local Institution - 0335, Xi'an, Shaanxi, China
🇺🇸
Local Institution - 0245, Fort Myers, Florida, United States
🇺🇸
Local Institution - 0009, Orange City, Florida, United States

and more 150 locations